OHSU

IRB #

IRB00009193

Title

A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy.

Principal Investigator

Cong-Qiu Chu

Study Purpose

To investigate the efficacy and safety of a study drug called baricitinib when used to treat severe active Rheumatoid Arthritis (RA) in those with inadequate response to Methotrexate.

Medical Condition(s)

Moderate to Severe Active Rheumatoid Arthritis (RA)

Eligibility Criteria

Males and Females, age 18 and older, with RA who are currently taking and having an inadquate response to methotrexate

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Participation could last up to 62 weeks - with the possibility of entering a long-term extension study.

Minors Included

No

Contact

Tim Noland
503.494.5742

Sponsor

Eli Lilly & Company

Recruitment End

05/30/2014

Compensation Provided

Yes

Compensation

Subjects will receive $42 for each study visit completed. If they complete the entire study they could receive up to $672.


Go Back